Embolotherapy Market: Current Analysis and Forecast (2025-2033)
Embolotherapy is an intervention method in medicine that involves purposefully blocking blood vessels to treat a number of conditions, with the majority being cancers, vascular malformations, and uncontrollable bleeding. It is performed by interventional radiologists under imaging guidance and involves the injection of embolic agents (microspheres, coils, plugs, or liquid) into a target site so as to limit blood flow. It may reduce or kill tumors by decreasing blood flow to the tumor, preventing bleeding, or slowing blood flow prior to surgery. Embolotherapy has the advantage of a shorter recovery period, less surgical risk, and preservation of organs, which makes embolotherapy a choice over the conventional open surgical procedures.
The Embolotherapy market is set to show a growth rate of about 8.1% during the forecast period (2025-2033F). The embolotherapy market is increasing because the target diseases, like liver cancer, uterine fibroids, and arteriovenous malformations, are also increasing. For instance, the WHO has stated that liver cancer is the 6th most common cancer worldwide. Liver cancer, uterine fibroids, and arteriovenous malformations are increasingly being treated using minimally invasive procedures. The evolution of embolic agents is on the rise, with the introduction of drug-eluting beads and bioresorbable materials, as well as liquid embolic agents, improving treatment precision, safety, and outcomes, thereby increasing adoption rates. Increase in demand is further motivated by the desire of patients to favor those procedures that have shorter recovery periods and lower complication rates. Moreover, the growth of interventional radiology centers, favorable reimbursement policies in developed countries, and increasing investments in healthcare in emerging markets are driving the market.
The Embolotherapy market is set to show a growth rate of about 8.1% during the forecast period (2025-2033F). The embolotherapy market is increasing because the target diseases, like liver cancer, uterine fibroids, and arteriovenous malformations, are also increasing. For instance, the WHO has stated that liver cancer is the 6th most common cancer worldwide. Liver cancer, uterine fibroids, and arteriovenous malformations are increasingly being treated using minimally invasive procedures. The evolution of embolic agents is on the rise, with the introduction of drug-eluting beads and bioresorbable materials, as well as liquid embolic agents, improving treatment precision, safety, and outcomes, thereby increasing adoption rates. Increase in demand is further motivated by the desire of patients to favor those procedures that have shorter recovery periods and lower complication rates. Moreover, the growth of interventional radiology centers, favorable reimbursement policies in developed countries, and increasing investments in healthcare in emerging markets are driving the market.
- Based on the product type category, the market is categorized into embolic agents and support devices. Among these, the embolic agents market holds the highest market share in the embolotherapy market, due to their broad utilization in procedures such as TACE, TARE, and uterine artery embolization, along with the broad range of available coils, particles, and liquid embolic to meet the clinical requirements of various procedures. However, in the future, the support devices market, including microcatheters, guidewires, and delivery systems, will advance at a higher rate, driven by technological innovations, the increasing use of minimally invasive procedures, and the need for precision in complex procedures. For instance, in July 2025, Embolx, which is a leader in advanced microcatheters for targeted embolization procedures, announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. Sniper G3 has a better tracking ability and less preparation time, making its pre-procedure setup time much less.
- Based on the procedure category, the market is categorized into Transcatheter Arterial Embolization [TAE], Transarterial Radioembolization/Selective Internal Radiation Therapy [TARE/SIRT], and Transarterial Chemoembolization [TACE]. Among these, the TACE segment currently holds the largest market share, as it is the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC), which is routinely performed in hospitals. Its use of embolization combined with localized chemotherapy has made it extremely popular to control tumors. However, the TARE/SIRT segment is expected to experience the highest growth rates in the future due to the growing use of Yttrium-90 microspheres, better survival rates, and a rising preference among patients and healthcare providers.
- Based on the indication category, the market is segmented into oncology, vascular disease, and others. Among these, the oncology segment holds the largest market share due to the growing popularity of embolotherapy procedures, such as TACE and TARE, in the treatment of hepatocellular carcinoma and other metastatic cancers. However, the vascular disease segment is expected to grow significantly in the forecasted period, due to the rising incidence of aneurysms, arteriovenous malformations, and peripheral vascular disorders.
- Based on the end-user category, the market is segmented into hospitals and clinics, ambulatory surgery centers, and others. Among these, the hospitals and clinics segment holds the largest market share because most embolotherapy is done in hospitals that have well-developed interventional radiology suites, specialized personnel, and post-procedure care facilities. However, in the future, ambulatory surgery centers (ASCs) are likely to show the most rapid growth due to the growing popularity of cost-efficient minimally invasive surgery, with shorter waiting periods. Technological innovations have enabled embolotherapy to be safely administered in outpatient settings, such as ASCs, thereby making it more accessible to patients.
- For a better understanding of the demand of embolotherapy, the market is analyzed based on its worldwide adoption in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and Rest of World. Among these, North America holds the maximum market share in the global embolotherapy market, primarily due to its advanced healthcare infrastructure, high adoption of minimally invasive procedures, and strong presence of leading medical device manufacturers. The demand for embolotherapy remains constant due to the high rates of occurrence of liver cancer, uterine fibroids, and vascular disorders. Furthermore, technological advancements, robust regulations in support of product approval, and the consolidation of image-guided therapies further enhance North America's dominance in the global market. The Asia Pacific region is, however, likely to be growing the fastest over the next years, driven by improving access to healthcare, rising investments in hospital infrastructure, and increasing awareness of embolotherapy’s benefits.
- Some major players running in the market include Boston Scientific Corporation, Merit Medical, Varian (Siemens Healthineers company), Darling Ingredients Inc., Terumo Medical Corporation, Stryker, Medtronic Inc., Kaneka Corporation, Instylla, Inc., and Acandis GmbH.
1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the Global Embolotherapy Market
2.2. Research Methodology of the Global Embolotherapy Market
2.3. Respondent Profile
3 EXECUTIVE SUMMARY
3.1. Industry Synopsis
3.2. Segmental Outlook
3.2.1. Market Growth Intensity
3.3. Regional Outlook
4 MARKET DYNAMICS
4.1. Drivers
4.2. Opportunity
4.3. Restraints
4.4. Trends
4.5. PESTEL Analysis
4.6. Demand Side Analysis
4.7. Supply Side Analysis
4.7.1. Merger & Acquisition
4.7.2. Collaboration & Investment Scenario
4.7.3. Industry Insights: Leading Startups and Their Unique Strategies
5 PRICING ANALYSIS
5.1. Regional Pricing Analysis
5.2. Price Influencing Factors
6 GLOBAL EMBOLOTHERAPY MARKET REVENUE (USD MN), 2023-2033F
7 MARKET INSIGHTS BY PRODUCT TYPE
7.1. Embolic Agents
7.2. Support Devices
8 MARKET INSIGHTS BY PROCEDURE
8.1. Transcatheter Arterial Embolization [TAE]
8.2. Transarterial Radioembolization/Selective Internal Radiation Therapy [TARE/SIRT]
8.3. Transarterial Chemoembolization [TACE]
9 MARKET INSIGHTS BY INDICATION
9.1. Oncology
9.2. Vascular Disease
9.3. Others
10 MARKET INSIGHTS BY END-USER
10.1. Hospitals and Clinics
10.2. Ambulatory Surgery Centres
10.3. Others
11 MARKET INSIGHTS BY REGION
11.1. North America
11.1.1. U.S.
11.1.2. Canada
11.1.3. Rest of North America
11.2. Europe
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Rest of Asia-Pacific
11.4. Rest of World
12 VALUE CHAIN ANALYSIS
12.1. Marginal Analysis
12.2. List of Market Participants
13 COMPETITIVE LANDSCAPE
13.1. Competition Dashboard
13.2. Competitor Market Positioning Analysis
13.3. Porter Five Forces Analysis
14 COMPANY PROFILES
14.1. Boston Scientific Corporation
14.1.1. Company Overview
14.1.2. Key Financials
14.1.3. SWOT Analysis
14.1.4. Product Portfolio
14.1.5. Recent Developments
14.2. Merit Medical
14.3. Varian (Siemens Healthineers Company)
14.4. Darling Ingredients Inc.
14.5. Terumo Medical Corporation
14.6. Stryker
14.7. Medtronic Inc.
14.8. Kaneka Corporation
14.9. Instylla, Inc.
14.10. Acandis GmbH
15 ACRONYMS & ASSUMPTION
16 ANNEXURE
1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the Global Embolotherapy Market
2.2. Research Methodology of the Global Embolotherapy Market
2.3. Respondent Profile
3 EXECUTIVE SUMMARY
3.1. Industry Synopsis
3.2. Segmental Outlook
3.2.1. Market Growth Intensity
3.3. Regional Outlook
4 MARKET DYNAMICS
4.1. Drivers
4.2. Opportunity
4.3. Restraints
4.4. Trends
4.5. PESTEL Analysis
4.6. Demand Side Analysis
4.7. Supply Side Analysis
4.7.1. Merger & Acquisition
4.7.2. Collaboration & Investment Scenario
4.7.3. Industry Insights: Leading Startups and Their Unique Strategies
5 PRICING ANALYSIS
5.1. Regional Pricing Analysis
5.2. Price Influencing Factors
6 GLOBAL EMBOLOTHERAPY MARKET REVENUE (USD MN), 2023-2033F
7 MARKET INSIGHTS BY PRODUCT TYPE
7.1. Embolic Agents
7.2. Support Devices
8 MARKET INSIGHTS BY PROCEDURE
8.1. Transcatheter Arterial Embolization [TAE]
8.2. Transarterial Radioembolization/Selective Internal Radiation Therapy [TARE/SIRT]
8.3. Transarterial Chemoembolization [TACE]
9 MARKET INSIGHTS BY INDICATION
9.1. Oncology
9.2. Vascular Disease
9.3. Others
10 MARKET INSIGHTS BY END-USER
10.1. Hospitals and Clinics
10.2. Ambulatory Surgery Centres
10.3. Others
11 MARKET INSIGHTS BY REGION
11.1. North America
11.1.1. U.S.
11.1.2. Canada
11.1.3. Rest of North America
11.2. Europe
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Rest of Asia-Pacific
11.4. Rest of World
12 VALUE CHAIN ANALYSIS
12.1. Marginal Analysis
12.2. List of Market Participants
13 COMPETITIVE LANDSCAPE
13.1. Competition Dashboard
13.2. Competitor Market Positioning Analysis
13.3. Porter Five Forces Analysis
14 COMPANY PROFILES
14.1. Boston Scientific Corporation
14.1.1. Company Overview
14.1.2. Key Financials
14.1.3. SWOT Analysis
14.1.4. Product Portfolio
14.1.5. Recent Developments
14.2. Merit Medical
14.3. Varian (Siemens Healthineers Company)
14.4. Darling Ingredients Inc.
14.5. Terumo Medical Corporation
14.6. Stryker
14.7. Medtronic Inc.
14.8. Kaneka Corporation
14.9. Instylla, Inc.
14.10. Acandis GmbH
15 ACRONYMS & ASSUMPTION
16 ANNEXURE
